ClinicalTrials.gg
CompletedNCT00682565Updated Aug 21, 2018Results posted

PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

A Phase 2 interventional study of CK-1827452 24mg and 6 mg iv infusion and CK-1827452 12.5mg capsule in Heart Failure, Myocardial Ischemia and Angina Pectoris, sponsored by Cytokinetics. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
5th of 14
94 · median 48
Started
2008
with 1 other
Phase 2
7 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 3rd registered.

Heart Failure

6,337 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy patients with angina is deleteriously affected by treatment with CK-1827452.

Read the detailed description

The primary objective of this study is to assess the effect of intravenous (i.v.) CK-1827452 on symptom-limited exercise tolerance in patients with ischemic cardiomyopathy and angina. The secondary objectives are to assess the tolerability of CK-1827452 administered three times daily (tid) to steady state in an immediate-release (IR), blend-in-capsule oral formulation to outpatients with ischemic cardiomyopathy and angina and to assess CK-1827452 plasma concentrations at trough and 1 hour after dosing with CK-1827452 administered tid to steady state in an IR, blend-in-capsule oral formulation to outpatients with ischemic cardiomyopathy and angina.

03

Conditions studied

  • Heart Failure
  • Myocardial Ischemia
  • Angina Pectoris
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has signed an Form/Patient Information Sheet for this study approved by the governing Institutional Review Board (IRB) or Independent Ethics Committee (IEC).
  2. The patient is at least 18 years old.
  3. The patient has ischemic heart disease documented by any one or more of the following:

    • A history of myocardial infarction documented by elevated CPK-MB, troponin I or T, or the presence of electrocardiographic Q waves consistent with myocardial infarction.
    • Coronary angiography demonstrating at least 1 major epicardial coronary artery (i.e., left main, left anterior descending, left circumflex, or right coronary artery) with a stenosis of at least 60% diameter or greater but excluding stenosis of the left main coronary artery unless revascularized by coronary artery bypass grafting.
  4. The patient has a history of ≥ 1 episode of exercise induced angina within 2 months prior to the initial screening visit.
  5. The patient has been taking a beta blocker and an ACE inhibitor (and/or an ARB) for at least 4 weeks. If prescribed, diuretics must have been administered for at least 4 weeks prior to the initial screening visit.
  6. The patient is Class II-III at the time of enrollment and has been so for ≥ 3 months prior to the initial screening visit.
  7. The patient has a history of a (LVEF) ≤ 35%.
  8. The patient has a history of EITHER a left ventricular end-diastolic diameter ≥ 55 mm, OR a left ventricular end-diastolic diameter index ≥ 32 mm/m2.
  9. The patient can be expected to complete at least 4 minutes of a Modified Naughton ETT (see Appendix B).
  10. For female patients only: The patient is (≥ 1 year) or sterilized, or if she is of , she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant during the course of the study, and she is using drugs or devices.

Exclusion criteria

Exclusion Criteria:

  1. The patient has acute myocarditis; restrictive, constrictive, or hypertrophic obstructive cardiomyopathy; or clinically significant congenital heart disease.
  2. The patient has a SBP > 160 mmHg, documented on at least 3 separate occasions, at least 10 minutes apart.
  3. The patient has a DBP > 90 mmHg, documented on at least 3 separate occasions, at least 10 minutes apart.
  4. The patient has levels of troponin I or T, or CPK-MB > the at any time from 6 weeks prior to the Initial Screening Visit (Visit 1) and up to randomization.
  5. The patient has severe aortic or mitral stenosis.
  6. The patient has had an acute coronary syndrome, , or revascularization procedure within 6 weeks of the Initial Screening Visit (Visit 1).
  7. The patient has significant co-morbid conditions (i.e., lung disease, arthritis, peripheral vascular disease) that may limit his or her treadmill exercise capacity.
  8. The patient has renal impairment defined by a calculated \< 30 cc/min or a need for renal replacement therapy.
  9. The patient has known hepatic impairment defined by a total > 3 mg/dL, or an or AST > 2 times the upper limit of normal.
  10. The patient has received an drug or device within 30 days or 5 half-lives, whichever is greater, of randomization.
  11. The patient weighs > 120 kg.
  12. The patient has a body temperature > 38 ° C, confirmed by at least 2 successive measurements, at least 10 minutes apart.
  13. The patient has any laboratory abnormality which, in the opinion of the investigator, should preclude his or her participation in the study.
  14. The patient has had any prior treatment with CK-1827452.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Mid Dose CK-1827452 or Placebo

    CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose

    Drug: CK-1827452 24mg and 6 mg iv infusion · Drug: CK-1827452 12.5mg capsule · Drug: Placebo iv infusion · Drug: Placebo capsule

  • Experimental
    High Dose CK-1827452 or Placebo

    CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose

    Drug: CK-1827452 48 mg and 11 mg iv infusion · Drug: CK-1827452 25mg capsule · Drug: Placebo iv infusion · Drug: Placebo capsule

Interventions

  • DrugCK-1827452 24mg and 6 mg iv infusion

    Drug page: Omecamtiv mecarbil

    I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr

    Also known as: omecamtiv mecarbil

  • 12.5mg oral immediate release capsule

    Also known as: omecamtiv mecarbil

  • DrugCK-1827452 48 mg and 11 mg iv infusion

    Drug page: Omecamtiv mecarbil

    I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr

    Also known as: omecamtiv mecarbil

  • 25mg oral immediate release capsule

    Also known as: omecamtiv mecarbil

  • DrugPlacebo iv infusion

    Matching placebo iv infusion

  • DrugPlacebo capsule

    Matching placebo oral immediate release capsule

06

What researchers measure

Primary outcomes

  1. Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)

    The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.

    Time frame: 1 day

Secondary outcomes

  1. Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B

    The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.

    Time frame: 1 day

  2. Increase in Exercise Duration During ETT-3 vs. ETT-B

    Time frame: 1 day

  3. Participants Stopping ETT-3 for Angina at Any Stage

    This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B. Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina.

    Time frame: 1 day

  4. Participants With 1 mm ST Segment Depression During ETT-3

    ST Segment Depression measured by Electrocardiography while performing ETT-3.

    Time frame: 1 day

07

Results

Posted Feb 25, 2010

Participant flow

Participant flow — Overall Study
MilestoneMid Dose CK-1827452High Dose CK-1827452Placebo
Started313529
Completed303229
Not completed130

Outcome measures

PrimaryParticipants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)

The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.

Time frame:
1 day
Reported as:
Number · Participants
Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)
ParticipantsMid Dose Active DrugHigh Dose Active DrugAll Placebo
Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)001
SecondaryParticipants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B

The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.

Time frame:
1 day
Reported as:
Number · Participants
Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B
ParticipantsMid Dose Active DrugHigh Dose Active DrugAll Placebo
Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B421
SecondaryIncrease in Exercise Duration During ETT-3 vs. ETT-B
Time frame:
1 day
Reported as:
Mean · seconds
Increase in Exercise Duration During ETT-3 vs. ETT-B
secondsMid Dose Active DrugHigh Dose Active DrugAll Placebo
Increase in Exercise Duration During ETT-3 vs. ETT-B41.5 ± 113.140.5 ± 70.660.1 ± 71.2
SecondaryParticipants Stopping ETT-3 for Angina at Any Stage

This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B. Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina.

Time frame:
1 day
Reported as:
Number · Participants
Participants Stopping ETT-3 for Angina at Any Stage
ParticipantsMid Dose Active DrugHigh Dose Active DrugAll Placebo
Participants Stopping ETT-3 for Angina at Any Stage072
SecondaryParticipants With 1 mm ST Segment Depression During ETT-3

ST Segment Depression measured by Electrocardiography while performing ETT-3.

Time frame:
1 day
Reported as:
Number · Participants
Participants With 1 mm ST Segment Depression During ETT-3
ParticipantsMid Dose Active DrugHigh Dose Active DrugAll Placebo
Participants With 1 mm ST Segment Depression During ETT-3012

Adverse events

Collected over 2 - 3 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Active Drug—0/31 (0%)2/31 (6.5%)
Cohort 2 Active Drug—1/34 (2.9%)7/34 (20.6%)
All Placebo—0/29 (0%)3/29 (10.3%)
Total—1/94 (1.1%)12/94 (12.8%)
Most frequent serious events
Most frequent serious events
EventCohort 1 Active DrugCohort 2 Active DrugAll PlaceboTotal
Acute Coronary SyndromeCardiac disorders0/311/340/291/94
Post-procedural Myocardial InfarctionInjury, poisoning and procedural complications0/311/340/291/94
Most frequent other events
Most frequent other events
EventCohort 1 Active DrugCohort 2 Active DrugAll PlaceboTotal
DyspneaRespiratory, thoracic and mediastinal disorders0/313/341/294/94
Ventricular ExtrasystolesCardiac disorders0/312/340/292/94
Infusion Site PainGeneral disorders1/310/341/292/94
PhotopsiaEye disorders0/311/341/292/94
HypotensionVascular disorders1/311/340/292/94

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Mid Dose Active DrugHigh Dose Active DrugAll PlaceboTotal
<=18 years0000
Between 18 and 65 years11161744
>=65 years20181250
Age, Continuous
Age, Continuous(years)Mid Dose Active DrugHigh Dose Active DrugAll PlaceboTotal
Mean65.2 ± 10.062.6 ± 8.162.3 ± 9.863.4 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Mid Dose Active DrugHigh Dose Active DrugAll PlaceboTotal
Female85619
Male23292375
Region of Enrollment
Region of Enrollment(participants)Mid Dose Active DrugHigh Dose Active DrugAll PlaceboTotal
Russian Federation014721
Georgia31202273
08

Study locations

14 sites
  • Tbilisi State Medical University Clinic #1
    Tbilisi, 0102, Georgia
  • Cardio-Reanimation Centre
    Tbilisi, 0141, Georgia
  • Cardiology Clinic
    Tbilisi, 0144, Georgia
  • National Center of Therapy
    Tbilisi, 0159, Georgia
  • Multiprofile Clinical Hospital of Tbilisi #2
    Tbilisi, 0164, Georgia
  • Diagnostic Services Clinic
    Tbilisi, 0179, Georgia
  • Altay Territory Cardiology Dispensary
    Barnaul, Russian Federation
  • City Hospital #1
    Barnaul, Russian Federation
  • City Clinical Hospital #59
    Moscow, Russian Federation
  • City Clinical Hospital #64
    Moscow, Russian Federation
  • Moscow Municipal Clinical Hospital #4
    Moscow, Russian Federation
  • Federal Center of Heart, Blood and Endocrinology n.a. Almazov
    St. Petersburg, Russian Federation
  • Research Centre for Cardiology n.a. Almazov under Roszdrav
    St. Petersburg, Russian Federation
  • Volgograd Regional Cardiology Center
    Volgograd, Russian Federation
09

References and documents

Publications

  • Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan;3(1):22-29. doi: 10.1016/j.jchf.2014.07.009. Epub 2014 Nov 11. Erratum In: JACC Heart Fail. 2020 Aug;8(8):700. doi: 10.1016/j.jchf.2020.06.007. PubMed 25453536 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Nov 2008 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2008
First posted
May 22, 2008
Start
Apr 2008
Primary completionActual
Nov 2008
CompletionActual
Mar 2009
Results first posted
Feb 25, 2010
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00682565
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
May 22, 2008
Start date
Apr 2008
Primary completion
Nov 2008
Completion
Mar 2009
Results posted
Feb 25, 2010
Last update
Aug 21, 2018

Study contacts

Andrew A Wolff, MD, FACC
study chair · Cytokinetics, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion